A Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.

Trial Profile

A Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2016

At a glance

  • Drugs TAS 115 (Primary)
  • Indications Solid tumours
  • Focus First in man; Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 02 Jun 2015 This trial was restarted in December 2013 with a new formulation of TAS 115 (the drug formulation was changed because of the saturation of absorption), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 12 Jan 2015 New source identified and integrated (Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information JapicCTI-111645).
    • 31 Dec 2014 Status changed from recruiting to completed, according to the Japan Pharmaceutical Information Center: JAPIC Clinical Trials Information record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top